上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
17期
75-80
,共6页
止吐药%5-HT3受体拮抗剂%NK-1受体拮抗剂
止吐藥%5-HT3受體拮抗劑%NK-1受體拮抗劑
지토약%5-HT3수체길항제%NK-1수체길항제
anti-emesis agents%5-HT3 receptor antagonist%NK-1 receptor antagonist
通过查询CFDA、FDA数据库，汇总分析国内外已上市止吐药的种类、生产批件数量、销售金额以及近3年产品注册申报情况，发现国内止吐药生产批件众多，且有不少企业仍在仿制，临床用药高度集中于5-HT3受体拮抗剂类品种，其销售金额占据止吐药98%的市场份额，市场呈平稳增长态势。然而，近年来随着新作用机理的NK-1受体拮抗剂类止吐药成功上市，止吐药市场格局将迎来新的变化，也给企业带来了新的机遇和挑战。因此，企业在抢夺市场先机之时应注意防范过度仿制带来的产品风险。
通過查詢CFDA、FDA數據庫，彙總分析國內外已上市止吐藥的種類、生產批件數量、銷售金額以及近3年產品註冊申報情況，髮現國內止吐藥生產批件衆多，且有不少企業仍在倣製，臨床用藥高度集中于5-HT3受體拮抗劑類品種，其銷售金額佔據止吐藥98%的市場份額，市場呈平穩增長態勢。然而，近年來隨著新作用機理的NK-1受體拮抗劑類止吐藥成功上市，止吐藥市場格跼將迎來新的變化，也給企業帶來瞭新的機遇和挑戰。因此，企業在搶奪市場先機之時應註意防範過度倣製帶來的產品風險。
통과사순CFDA、FDA수거고，회총분석국내외이상시지토약적충류、생산비건수량、소수금액이급근3년산품주책신보정황，발현국내지토약생산비건음다，차유불소기업잉재방제，림상용약고도집중우5-HT3수체길항제류품충，기소수금액점거지토약98%적시장빈액，시장정평은증장태세。연이，근년래수착신작용궤리적NK-1수체길항제류지토약성공상시，지토약시장격국장영래신적변화，야급기업대래료신적궤우화도전。인차，기업재창탈시장선궤지시응주의방범과도방제대래적산품풍험。
It is found that there are many domestic production approvals in anti-emesis agents, and many domestic enterprises have been working on the production of this kind of generic drug by querying CFDA and FDA database, summarizing and analyzing the types of anti-emesis agents already on the international and domestic markets, the number of production license, sales and the applications of production registration in three years. Clinical medication is highly focused on 5-HT3 receptor antagonist, the sales of which account for 98%market share of anti-emesis agents and the marketing trend has been steadily increasing. However, antiemetic market pattern will also usher in a new change and the pharmaceutical enterprises will be faced with new opportunities and challenges with NK-1 receptor antagonists as new anti-emesis being successfully marketed in recent years. Therefore, enterprises should pay attention to the risks resulting from the excessive imitation production while capturing the market.
